Cooley-Led BioPharma Raises $96M In IPO At Top Of Range
Clinical-stage biopharmaceutical company Keros Therapeutics Inc. started trading shares Wednesday after raising $96 million in a Cooley LLP-steered initial public offering that priced at the top of its expected range....To view the full article, register now.
Already a subscriber? Click here to view full article